Response to Beasley CW, Moore WH, and Wagner LK

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90468/1/thy-2E2011-2E0181-2Ers.pd

Response to Hennessey et al.

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/98489/1/thy%2E2011%2E0378%2Ers.pd

Northerly Movement of Corn Borer Moths in Southern Minnesota

Seventeen light traps were installed in 6 counties in southwest Minnesota in 1962 and 1963 and the nightly catches of moths of the European corn borer were recorded. The results show that moth catch was higher during nights with south winds and the nights immediately following such nights. This relation occurred over a large area and during the entire flight period. Moth popu1\u27otion in southern Minnesota was increased when south winds prevailed during the Right period. The trapping and recording were carried out by 15 FFA members, l 4-H member, and l adult farmer. The project demonstrates that these young people represent a valuable pool of human resources for use in salving certain scientific problems

Courses of Malignant Pheochromocytoma

Survival of patients with metastatic pheochromocytoma that have exceeded 30 years without therapy to reduce tumors have been reported. We reviewed the records of 38 patients with malignant pheochromocytoma who had received 131 I-metaiodiobenzylguanidine ( 131 I-MIBG) treatments between 1981 and 1996 to evaluate longevity. Survival from diagnosis to last follow-up exceeded 5 years in 21 of 38 (55%) and ≥10 years in 50%. In 17 of 21, the interval from diagnosis to 131 I-MIBG therapy was greater than 5 years. Survival following 131 I-MIBG was ≥5 years in 12 of 17 and ≥10 years in 7 of 17 patients despite continued evidence of excessive circulating catecholamines. Objective responses to 131 I-MIBG therapy were seen in about 30% and were usually of a few years, duration, but one individual exhibited marked reductions in volume and function of tumors that have persisted for 21 years. No feature, including a remission of >5 years following surgical excision, was found to predict prolonged survival. In summary, many patients with malignant pheochromocytoma will follow a course extending over many years. The role of 131 I-MIBG therapy in longevity is uncertain, but this radiopharmaceutical reduces evidence of tumors in some patients. Criteria for selecting patients who will benefit from treatment remain to be determined.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/73567/1/annals.1353.053.pd

Three Endocrine Neoplasms: An Unusual Combination of Pheochromocytoma, Pituitary Adenoma, and Papillary Thyroid Carcinoma

Background: Three endocrine neoplasms?bilateral pheochromocytomas, somatotrophic pituitary adenoma inducing acromegaly, and papillary carcinoma of the thyroid?occurred concurrently in a patient. A genetic mutation was hypothesized. Possible previously described genetic mutations were explored. Methods: Clinical assessments, laboratory data, images of tumors, histopathology, and immunohistochemistry of excised tissues documented the three neoplasms. Clinical assessment of the patient, family history, and a review of the literature sought a familial basis for the disorders. Results: The methods confirmed the presence of three endocrine neoplasms. Each neoplasm was surgically excised and histologically verified. Surgical and 131I treatments reduced the papillary carcinoma, but eventually this tumor progressed to a lethal degree. History, including that of nine siblings, uncovered no familial neoplasms. No similar case was found in the literature, but possible associations with germline mutations were considered. Conclusions: The concurrent development of pheochromocytomas, pituitary somatotrophic adenoma, and papillary thyroid carcinoma appears to be unique. Nevertheless, such tumors, particularly bilateral pheochromocytomas, strongly suggest a de novo germline mutation in a gene not previously associated with multiple endocrine neoplasia syndromes.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/98488/1/thy%2E2011%2E0345.pd